Latest Content

Simvera PSP applies queueing science so manufacturers can test the cost and patient impact of hub staffing decisions before locking them in.

Gregg Gorniak explains how AI, RFID and serialized data are helping trading partners move DSCSA compliance from a regulatory checkbox to a source of shared operational value.

As HRSA's 340B Rebate Model Pilot moves toward its effective date, Valerie Bandy, PharmD, of Tecsys explains what drug-by-drug rebate tracking really demands from hospital and health system pharmacies.

Pharma pricing shifts beyond PBM rebates as Medicare and cash channels reshape launches, WAC cuts and access strategies.

In the final installment of his interview with Pharmaceutical Commerce, Cencora's Ameer Ali outlines how supply chain stakeholders should prepare systems, processes and trading partners for the shift to NDC-12.

In the final installment of his interview with Pharmaceutical Commerce, Cencora's Gregg Gorniak looks back at DSCSA's five-year evolution and where serialized data is creating value beyond compliance.

Authenticx CEO Amy Brown on why patient support AI needs continuous oversight, not just adoption.

HDA's Kala Shankle unpacks the biggest open question on preemption and offers a two-step playbook for wholesalers and 3PLs preparing for national licensure.

In this week's Pharma Pulse, DHL breaks ground on a new cold chain hub at Singapore's Changi Airport, a new report finds pharma's commercial model in the middle of a fundamental reset, and the FDA grants accelerated approval to sevabertinib.

Cardinal Health's Liberty Dewey outlines the four parallel work streams driving the NDC-12 transition, and why the biggest risk sits in trading partner handoffs rather than any single system.

Joe Reynolds, Head of User Experience Services at Noble, breaks down what it really takes for pharmaceutical companies to move therapy from the clinic into the patient's home.

Logan Melchione shares how ClaimGuardRx gives account teams a fast, conversational way to tackle diversion and fraud together, and what that means for clients and patients.

Bryan Dennison breaks down the purpose-built technology behind ClaimGuardRx and how its detect-and-respond design keeps manufacturers ahead of evolving diversion tactics.